Director/PDMR Shareholding

MGC Pharmaceuticals Limited

18 May 2023

 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 May 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Nicole Godresse
2	Reason for the notification
(a)	Position		Global Chief Sales Officer MGC Medical
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Disposal of shares
(d)	Currency	Price		Volume	Total
	AUD	$0.007		876,636	$6,136
	Aggregated information
	AUD	$0.007		876,636	$6,136
(e)	Date of transaction		2023-05-16
(f)	Place of transaction		Australian Stock Exchange

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Amir Polak
2	Reason for the notification
(a)	Position		Chief Pharmaceutical Development Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Disposal of shares
(d)	Currency	Price		Volume	Total
	AUD	$0.007		500,000	$3,500
	Aggregated information
	AUD	$0.007		500,000	$3,500
(e)	Date of transaction		2023-05-17
(f)	Place of transaction		Australian Stock Exchange

--Ends-

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd      Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Arron Canicais / Rowan Harland Joint Company Secretaries [phone] [e-mail]
UK PR Advisors Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]	UK Brokers Peterhouse Capital Charles Goodfellow / Lucy Williams [phone] [e-mail] / [e-mail]
UK Financial and Corporate Advisor SW4 Partners Rupert Fane / Nilesh Patel [e-mail]  / [e-mail]

 

END